LONDON, June 17, 2021 – Covington advised Arecor Therapeutics plc on the admission of its shares to trading on the AIM market of the London Stock Exchange. The IPO raised gross proceeds of £20 million through an oversubscribed placing of ordinary shares giving the company a market capitalisation of approximately £62.5 million.
Funding to accelerate clinical progression of Iksuda’s pipeline of new generation of antibody drug conjugates, targeting tumours with high unmet need
Investment round led by Korean-based Mirae Asset Capital and Celltrion
Fieldfisher's top ranked equity capital markets team has advised Panmure Gordon as sole broker on an oversubscribed fundraising for AIM-listed Diurnal Group plc, a specialist pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases.
Oxford, UK, May 10 2021 – Magdalen College Oxford, owner of The Oxford Science Park (TOSP), one of the UK’s leading parks for science and technology companies, has announced that it is seeking a strategic partner with which to accelerate development of the Park.
In recent years (CROs) have become the backbone of pharma and biotech research and development (R&D), the go-to source for in-depth know-how and niche expertise no longer available within such organisations. In recent years, the CRO sector has boomed. Despite being squeezed hard by COVID-19, according to new analysis out by Frost and Sullivan, the global market should still grow to $63.83 billion by 2024 from $43.03 billion in 2019, at a compound annual growth rate of 8.2%.
The Chancellor has said that business support measures such as Furlough will continue, and more money has been made available to vaccine programmes. But alongside these measures to mitigate the impact of the pandemic, there was a promise of more investment in science and tech scale-ups, improvements to R&D tax credits to incentivise cutting edge science to be conducted in the UK, and rule changes to make it easier to list on the London Stock Exchange.
European law firm Fieldfisher has advised AIM-quoted Synairgen plc, a leading respiratory disease drug discovery company based in Southampton, on its £87 million fundraising to begin the Phase III trial for a potential inhaled treatment for COVID-19